Compare Gilead Sciences, Inc. (GILD) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Linde PLC — how do they compare? Gilead Sciences, Inc. trades at $133.55 (market cap $163.51B), while Linde PLC trades at $514.87 (market cap $237.72B). The key difference: Linde PLC is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | LIN | |
|---|---|---|
Market Cap | $163.51B | $237.72B |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $546.64 |
52-Week Low | $108.22 | $389.38 |
Enterprise Value | $178.05B | $260.07B |
Dividend Yield | 2.49% | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Linde (LIN) trades at $522.54, down 0.29% on the day, with a bullish technical signal from moving averages and oversold RSI suggesting potential rebound. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $4.33 (beat), and robust profitability with a 20.44% net margin. Recent news highlights sustainability leadership and Q1 results showing 10% EPS growth.
Outlook remains positive given analyst consensus (85.7% buy ratings) and a $560 price target, though high valuation multiples (P/E 34.65) pose a risk if growth moderates. Key risks include rising debt-to-asset ratio (31.63% in 2025) and macroeconomic pressures on industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
